Literature DB >> 1017716

Galactose elimination capacity as a prognostic index in patients with fulminant liver failure.

L Ranek, P B Andreasen, N Tygstrup.   

Abstract

In 25 patients with fulminant hepatic failure the prognostic value of a quantitative liver function test, the galactose elimination capacity, was assessed and comapred with routine liver function tests and clinical features. The galactose elimination capacity was significantly higher (P less than 0-05) in the five patients who survived than in the 20 patients who died. None of the other liver function tests, was significantly different. The values of the galactose elimination capacity overlapped considerably between survivors and non-survivors, but all patients with a galactose elimination capacity below 12-8 mumol galactose/min and kg body weight died. The disease among most patients who died having a galactose elimination capacity greater than 13 mumol ran a subacute course. It is suggested that quantitative liver function tests be included when new treatments of fulminant hepatic failure are investigated.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1017716      PMCID: PMC1411226          DOI: 10.1136/gut.17.12.959

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Liver failure and drug metabolism.

Authors:  P B Andreasen; L Ranek
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

2.  The urinary excretion of galactose and its significance in clinical intravenous galactose tolerance tests.

Authors:  N TYGSTRUP
Journal:  Acta Physiol Scand       Date:  1961 Feb-Mar

Review 3.  The treatment of acute liver failure.

Authors:  S J Saunders; R Hickman; R Macdonald; J Terblanche
Journal:  Prog Liver Dis       Date:  1972

4.  Long term follow-up studies of patients surviving fluminant viral hepatitis.

Authors:  G G Karvountzis; A G Redeker; R L Peters
Journal:  Gastroenterology       Date:  1974-11       Impact factor: 22.682

5.  Discriminative and prognostic signs in acute hepatic coma, treated by exchange transfusions.

Authors:  M Demedts; J De Groote; B Vandamme; V J Desmet
Journal:  Digestion       Date:  1974       Impact factor: 3.216

6.  Charcoal haemoperfusion in the treatment of fulminant hepatic failure.

Authors:  B G Gazzard; M J Weston; I M Murray-Lyon; H Flax; C O Record; R Williams; B Portmann; P G Langley; E H Dunlop; P J Mellon; M B Ward
Journal:  Lancet       Date:  1974-06-29       Impact factor: 79.321

7.  Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage.

Authors:  L F Prescott; P Roscoe; N Wright; S S Brown
Journal:  Lancet       Date:  1971-03-13       Impact factor: 79.321

8.  Acute hepatic failure treated by cross circulation.

Authors:  J M Burnell; C Runge; F C Saunders; E D Thomas; W Volwiler
Journal:  Arch Intern Med       Date:  1973-10

9.  Heterologous liver perfusion in treatment of hepatic failure.

Authors:  B Eiseman; D S Liem; F Raffucci
Journal:  Ann Surg       Date:  1965-09       Impact factor: 12.969

10.  Pig liver perfusion in the treatment of acute hepatic failure.

Authors:  L Ranek; R I Hansen; M Hilden; K Ramsöe; A Schmidt; K Winkler; N Tygstrup
Journal:  Scand J Gastroenterol Suppl       Date:  1971
View more
  18 in total

Review 1.  Liver regeneration in relationship to acute liver failure.

Authors:  C D Gove; R D Hughes
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Preoperative galactose elimination capacity predicts complications and survival after hepatic resection.

Authors:  Claudio A Redaelli; Jean-François Dufour; Markus Wagner; Martin Schilling; Jürg Hüsler; Lukas Krähenbühl; Markus W Büchler; Jürg Reichen
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

3.  Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis.

Authors:  J Reichen; B Egger; N Ohara; T B Zeltner; T Zysset; A Zimmermann
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  Prognostic value of the oculovestibular reflex in fulminant hepatic failure.

Authors:  M A Hanid; D B Silk; R Williams
Journal:  Br Med J       Date:  1978-04-22

Review 5.  Quantitative PET of liver functions.

Authors:  Susanne Keiding; Michael Sørensen; Kim Frisch; Lars C Gormsen; Ole Lajord Munk
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

Review 6.  Preoperative liver function assessments to estimate the prognosis and safety of liver resections.

Authors:  Toru Mizuguchi; Masaki Kawamoto; Makoto Meguro; Thomas T Hui; Koichi Hirata
Journal:  Surg Today       Date:  2013-03-09       Impact factor: 2.549

7.  Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.

Authors:  Michael Sørensen; Kasper S Mikkelsen; Kim Frisch; Gerda E Villadsen; Susanne Keiding
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

8.  Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?

Authors:  Christoph Herold; Sabine Regn; Marion Ganslmayer; Matthias Ocker; Eckhart G Hahn; Detlef Schuppan
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

9.  Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.

Authors:  S Madsbad; B Bjerregaard; J H Henriksen; E Juhl; H Kehlet
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

10.  Hepatitis type A, B, and non-A non-B in fulminant hepatitis.

Authors:  L R Mathiesen; P Skinoj; J O Nielsen; R H Purcell; D Wong; L Ranek
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.